219 related articles for article (PubMed ID: 29506546)
1. Analysis of prognostic factors of patients with malignant peritoneal mesothelioma.
Yin W; Zheng G; Yang K; Song H; Liang Y
World J Surg Oncol; 2018 Mar; 16(1):44. PubMed ID: 29506546
[TBL] [Abstract][Full Text] [Related]
2. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
Fujimoto E; Kijima T; Kuribayashi K; Negi Y; Kanemura S; Mikami K; Doi H; Kitajima K; Nakano T
Expert Rev Anticancer Ther; 2017 Sep; 17(9):865-872. PubMed ID: 28594258
[TBL] [Abstract][Full Text] [Related]
3. The Value of COX-2, NF-κB, and Blood Routine Indexes in the Prognosis of Malignant Peritoneal Mesothelioma.
Yin W; Zheng G; Su S; Liang Y
Oncol Res Treat; 2019; 42(6):334-341. PubMed ID: 31063993
[TBL] [Abstract][Full Text] [Related]
4. Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas.
Cihan YB; Ozturk A; Mutlu H
Asian Pac J Cancer Prev; 2014; 15(5):2061-7. PubMed ID: 24716935
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.
Nagata Y; Sawada R; Takashima A; Shoji H; Honma Y; Iwasa S; Amano K; Kato K; Hamaguchi T; Shimada Y; Saruta M; Boku N
Jpn J Clin Oncol; 2019 Dec; 49(11):1004-1008. PubMed ID: 31287877
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study.
Kitadai R; Shimoi T; Sudo K; Noguchi E; Nagata Y; Sawada R; Takashima A; Boku N; Yonemori K
BMC Cancer; 2021 Mar; 21(1):294. PubMed ID: 33743636
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases.
Nakano M; Kusaba H; Makiyama A; Ariyama H; Arita S; Oda H; Esaki T; Takayoshi K; Uchino K; Tamura S; Kumagai H; Iwama E; Shirakawa T; Mitsugi K; Takaishi S; Akashi K; Baba E
Anticancer Res; 2014 Jan; 34(1):215-20. PubMed ID: 24403465
[TBL] [Abstract][Full Text] [Related]
8. IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma.
Hui S; Guo-Qi Z; Xiao-Zhong G; Chun-Rong L; Yu-Fei L; Dong-Liang Y
Hum Pathol; 2018 Nov; 81():138-147. PubMed ID: 30031101
[TBL] [Abstract][Full Text] [Related]
9. Malignant Peritoneal Mesothelioma: Treatment Options and Survival.
Salo SAS; Ilonen I; Laaksonen S; Myllärniemi M; Salo JA; Rantanen T
Anticancer Res; 2019 Feb; 39(2):839-845. PubMed ID: 30711965
[TBL] [Abstract][Full Text] [Related]
10. The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication.
Hooper CE; Lyburn ID; Searle J; Darby M; Hall T; Hall D; Morley A; White P; Rahman NM; De Winton E; Clive A; Masani V; Arnold DT; Dangoor A; Guglani S; Jankowska P; Lowndes SA; Harvey JE; Braybrooke JP; Maskell NA
Br J Cancer; 2015 Mar; 112(7):1175-82. PubMed ID: 25756396
[TBL] [Abstract][Full Text] [Related]
11. Diffuse malignant biphasic peritoneal mesothelioma with cystic areas.
Cabibi D; Tutino R; Salamone G; Cocorullo G; Agrusa A; Gulotta G
Ann Ital Chir; 2016 Jun; 87():. PubMed ID: 27320084
[TBL] [Abstract][Full Text] [Related]
12. [Clinical features of patients with malignant peritoneal mesothelioma initially presenting as a local inflammation].
Song H; Zheng G; Wei S; Yang Y; Wei X
Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):312-3. PubMed ID: 24989921
[No Abstract] [Full Text] [Related]
13. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival.
Sugarbaker PH; Chang D
Eur J Surg Oncol; 2017 Jul; 43(7):1228-1235. PubMed ID: 28189456
[TBL] [Abstract][Full Text] [Related]
14. [A case of malignant peritoneal mesothelioma with the epithelioid histological type, successfully treated with pemetrexed plus cisplatin].
Kobayashi M; Moriwaki T; Ochi D; Saito R; Kobayashi K; Sugaya A; Akutsu D; Hamano Y; Imanishi M; Yamamoto Y; Yamada T; Nakano N; Sugano M; Hara K; Hyodo I
Gan To Kagaku Ryoho; 2014 Mar; 41(3):361-4. PubMed ID: 24743284
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma.
Yamagishi T; Fujimoto N; Nishi H; Miyamoto Y; Hara N; Asano M; Fuchimoto Y; Wada S; Kitamura K; Ozaki S; Kishimoto T
Lung Cancer; 2015 Oct; 90(1):111-7. PubMed ID: 26259877
[TBL] [Abstract][Full Text] [Related]
16. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
Fujimoto N; Aoe K; Kozuki T; Oze I; Kato K; Kishimoto T; Hotta K
Clin Lung Cancer; 2018 Sep; 19(5):e705-e707. PubMed ID: 29853412
[TBL] [Abstract][Full Text] [Related]
17. [A Case of Malignant Peritoneal Mesothelioma Treated with Cisplatin and Pemetrexed].
Sone T; Omori S; Hayashi K; Yamato H; Ohira K; Kondo N; Takagi Y; Kato K
Gan To Kagaku Ryoho; 2018 Jun; 45(6):993-995. PubMed ID: 30026430
[TBL] [Abstract][Full Text] [Related]
18. [A case of malignant peritoneal mesothelioma diagnosed with laparoscopic biopsy].
Yagi Y; Maeda T; Yoshimitsu Y; Sakuma H
Gan To Kagaku Ryoho; 2014 Aug; 41(8):995-7. PubMed ID: 25132032
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment Controlling Nutritional Status Score and Lactate Dehydrogenase as Predictive Markers of Survival in Patients with Malignant Peritoneal Mesothelioma.
Wang QQ; Zheng GQ; Yang DL; Liang YF; Yin WJ; Su SS
Nutr Cancer; 2018; 70(8):1264-1274. PubMed ID: 30663400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
